177-Lu PSMA Therapy in Bedridden Patients with Hormone-Refractory Prostate Cancer

Eligibility Assessment for Bedridden Patients

• The American Urological Association suggests that 177-Lu-PSMA-617 therapy can be offered to bedridden patients with metastatic castration-resistant prostate cancer who have received prior docetaxel and androgen pathway inhibitor therapy with PSMA-positive disease, but careful assessment of performance status, renal function, and bone marrow reserve is critical given the increased toxicity risk in this vulnerable population 1, 2
• The European Association of Urology notes that patients with ECOG performance status >2 were excluded from pivotal trials, creating uncertainty about benefit-to-risk ratio in bedridden patients 1, 2

Mandatory Pre-Treatment Requirements

• The National Comprehensive Cancer Network recommends confirming PSMA-positive disease with PSMA PET imaging showing at least one PSMA-avid metastatic lesion 1, 2, 5
• The American Society of Clinical Oncology suggests documenting prior treatment with at least one androgen receptor pathway inhibitor and at least one taxane-based chemotherapy 1, 2, 5

Treatment Protocol Modifications for High-Risk Patients

• The European Society for Medical Oncology recommends administering 7.4 GBq (200 mCi) intravenously every 6 weeks for 4-6 cycles total 1, 2, 5
• The American College of Radiology suggests continuing concurrent androgen deprivation therapy and androgen pathway inhibitor during 177-Lu-PSMA-617 treatment, as the VISION trial demonstrated survival benefit with continued therapy 5

Expected Outcomes and Realistic Prognostication

• The American Society of Clinical Oncology reports a median overall survival improvement of 4.0 months and median progression-free survival improvement of 5.3 months 3, 4, 1, 2

Critical Pitfalls and Contraindications

• The National Comprehensive Cancer Network advises against administering 177-Lu-PSMA-617 to patients with severe renal impairment or end-stage renal disease, as pharmacokinetics and safety have not been studied in this population 1, 2
• The European Association of Urology suggests considering alternative palliative approaches if ECOG performance status is 4 with limited life expectancy (<3 months), as the median time to benefit is approximately 2-3 months 1, 2

Alternative Considerations

• The American Urological Association recommends considering cabazitaxel or best supportive care with continued androgen pathway inhibition if 177-Lu-PSMA therapy is deemed too risky or impractical for a bedridden patient 3, 4